Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25065229 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3EPHX2KDM1A | |
| SCHEMBL25065230 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3EPHX2KDM1A | |
| SCHEMBL31267867 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM3EPHX2KDM1A | |
| SCHEMBL24248698 | 0.85 | KDM1A (0.34) | CHRM2CHRM1CHRM3EPHX2KDM1A | |
| SCHEMBL25092596 | 0.83 | EPHX2 (0.32) | EPHX2KDM1A | |
| SCHEMBL25092593 | 0.83 | EPHX2 (0.32) | EPHX2KDM1A | |
| SCHEMBL22324204 | 0.79 | — | — | |
| SCHEMBL22324114 | 0.79 | — | — | |
| SCHEMBL30277219 | 0.77 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX2KDM1A | |
| SCHEMBL31488454 | 0.77 | CHRM2 (0.36) | CHRM2CHRM1CHRM3EPHX2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CHRM2 4693/4885CHRM1 4664/4885CHRM3 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.